PuSH - Publikationsserver des Helmholtz Zentrums München

Shevtsov, M* ; Multhoff, G.

Immunological and translational aspects of NK cell-based antitumor immunotherapies.

Front. Immunol. 7:492 (2016)
Verlagsversion DOI
Open Access Gold
Creative Commons Lizenzvertrag
Natural killer (NK) cells play a pivotal role in the first line of defense against cancer. NK cells that are deficient in CD3 and a clonal T cell receptor (TCR) can be subdivided into two major subtypes, CD56dimCD16+ cytotoxic and CD56brightCD16 immunoregulatory NK cells. Cytotoxic NK cells not only directly kill tumor cells without previous stimulation by cytotoxic effector molecules, such as perforin and granzymes or via death receptor interactions, but also act as regulatory cells for the immune system by secreting cytokines and chemokines. The aim of this review is to highlight therapeutic strategies utilizing autologous and allogenic NK cells, combinations of NK cells with monoclonal antibodies to induce antibody-dependent cellular cytotoxicity, or immune checkpoint inhibitors. Additionally, we discuss the use of chimeric antigen receptor-engineered NK cells in cancer immunotherapy.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter natural killer cell, immunotherapy, monoclonal antibody, antibody-dependent cellular cytotoxicity, checkpoint inhibitors, chimeric antigen receptor; Natural-killer-cells; Chimeric Antigen Receptor; Phase-i Trial; Tumor-cells; T-cells; Colorectal-cancer; Multiple-myeloma; Nk-92 Cells; Adoptive Immunotherapy; Bispecific Antibodies
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Quellenangaben Band: 7, Heft: , Seiten: , Artikelnummer: 492 Supplement: ,
Verlag Frontiers
Verlagsort Lausanne
Begutachtungsstatus Peer reviewed